Abstract
The present status of the neuroblastoma mass screening program in Japan, the first national trial in the world, is evaluated. This program, now in its fifth year, was conducted in cooperation with the infants' mothers, local health centers, screening centers, and selected hospitals. From the onset of the program in Kyoto in 1973 to the end of 1989, 337 cases were detected and analyzed. Most cases were detected at early stages and 97% are expected to be cured. Several social, technical, and clinical problems remain unresolved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Abdominal Neoplasms / epidemiology
-
Abdominal Neoplasms / pathology
-
Abdominal Neoplasms / prevention & control
-
Abdominal Neoplasms / urine
-
Age Factors
-
Biomarkers, Tumor / urine*
-
Child, Preschool
-
Chromatography, High Pressure Liquid
-
Homovanillic Acid / urine*
-
Humans
-
Incidence
-
Infant
-
Infant, Newborn
-
Interinstitutional Relations
-
Japan / epidemiology
-
Mass Screening* / organization & administration
-
Mediastinal Neoplasms / epidemiology
-
Mediastinal Neoplasms / pathology
-
Mediastinal Neoplasms / prevention & control
-
Mediastinal Neoplasms / urine
-
National Health Programs* / organization & administration
-
Neoplasm Regression, Spontaneous
-
Neoplasm Staging
-
Neuroblastoma / epidemiology
-
Neuroblastoma / pathology
-
Neuroblastoma / prevention & control*
-
Neuroblastoma / urine
-
Parents / psychology
-
Predictive Value of Tests
-
Reagent Kits, Diagnostic / standards
-
Survival Rate
-
Vanilmandelic Acid / urine*
Substances
-
Biomarkers, Tumor
-
Reagent Kits, Diagnostic
-
Vanilmandelic Acid
-
Homovanillic Acid